Ask about this productRelated genes to: NTRK3 antibody
- Gene:
- NTRK3 NIH gene
- Name:
- neurotrophic receptor tyrosine kinase 3
- Previous symbol:
- -
- Synonyms:
- TRKC
- Chromosome:
- 15q25.3
- Locus Type:
- gene with protein product
- Date approved:
- 1991-07-18
- Date modifiied:
- 2016-10-05
Related products to: NTRK3 antibody
Related articles to: NTRK3 antibody
- gene fusions are oncogenic drivers for a variety of adult and pediatric tumors, making them a target for tumor-agnostic precision medicine. Tropomyosin receptor kinase (TRK) inhibitors are approved by the US Food and Drug Administration for cancers driven by TRK fusions. However, genes can fuse with many different partner genes, leading to diverse TRK fusion proteins, highlighting the importance of identifying the specific fusion partner with optimal pan-cancer diagnostics. This analysis aims to provide an updated descriptive compendium of gene fusions. - Source: PubMed
Publication date: 2026/05/06
Yang Soo-RyumRepetto MatteoRudzinski Erin RLi Marilyn MRoy AngshumoyGutstein LaurenHuang KarenWu JinhuaGlade Bender JuliaBrega NicolettaBuchberg Arthur MBernard-Gauthier VadimHong David SDrilon AlexanderLaetsch Theodore W - Gene fusions involving neurotrophic tyrosine receptor kinase (NTRK) genes represent uncommon genetic alterations that may occur across a wide spectrum of tumor types. NTRK-rearranged sarcomas are most frequently identified in pediatric mesenchymal neoplasms, although they have also been described, less commonly, in adult mesenchymal tumors. We present the case of a 28-year-old woman with a large pelvic mass arising in relation to the psoas muscle. It was histologically composed of a dual cell population consisting of small hyperchromatic irregular cells intermixed with markedly pleomorphic "monster cells". Immunohistochemistry showed diffuse p16, Factor XIIIa, and CD163 positivity, while S100 protein, CD34, CD68 and other lineage-specific markers were negative. Pan-TRK immunostaining was negative. Targeted next-generation sequencing (NGS) was performed due to the non-specific findings of the tumor in a young adult patient, and a STRN::NTRK3 gene fusion involving exon 3 and exon 14, respectively, was identified, establishing this tumor as part of the emerging group of NTRK-rearranged neoplasms. Entrectinib was administered, and an excellent response was observed. This case emphasizes the relevance of performing NGS in cases with unusual clinicopathological findings to identify potential treatment options. Importantly, the morphology deviated from the classic fibrosarcoma-like appearance described in most adult NTRK3-fused neoplasms and broadens the morphological spectrum in which these neoplasms should be considered. - Source: PubMed
Publication date: 2026/05/06
Pena-Burgos Eva ManuelaSuárez-González JuliaHernández Muñoz LourdesArregui Valles MartaAsencio Jose ManuelMora-Díaz RodrigoPozo-Kreilinger Jose Juan - Epithelioid fibrous histiocytoma (EFH) is a benign cutaneous neoplasm that is now recognized to be largely driven by rearrangements. Rare cases of EFH and EFH-spectrum tumors with other receptor tyrosine kinase (RTK) fusions including and have been described, demonstrating the molecular heterogeneity of this entity. Herein, we report a 9-year-old female with a 1.5 cm right lateral chest wall lesion showing classic EFH morphology. Histology demonstrated a nodular dermal tumor extending to dermo-epidermal junction above and subcutaneous tissue below. The lesion was characterized by sheets of bland epithelioid/histiocytoid cells with a vaguely whorled architecture, prominent vessels, focal myxoid stroma, and no significant atypia, mitoses, or necrosis. On immunohistochemistry, the lesional cells were highlighted by CD68 and CD163, with patchy CD99 positivity. The lesional cells were negative for AE1/AE3, CD34, SMA, Desmin, S100, SOX10, CD10, ERG, CD1a, Langerin, CD30, and CD31. INI-1 was retained. Targeted solid tumor fusion analysis showed an fusion. This case expands the molecular spectrum of EFH beyond rearrangements and previously described and fusions. - Source: PubMed
Publication date: 2026/05/05
Challa BinduNaous RanaKirschner RichardReshmi Shalini CPrasad Vinay - Molecular testing has emerged as a pivotal tool for the preoperative assessment of cytologically indeterminate thyroid nodules. In this cross-sectional study, we evaluated the diagnostic utility of a targeted next-generation sequencing (NGS) 4-gene panel, including BRAF, TERT promoter mutations, RET fusions, and NTRK3 fusion, for enhancing the cytological diagnosis of thyroid nodules prior to surgical intervention. A total of 827 thyroid nodules subjected to fine-needle aspiration and subsequent histopathological confirmation were analyzed, among which 773 (93.5%) were classified as malignant or noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). The observed prevalence of molecular alterations was: BRAF, 68.3% (526/770); TERT promoter mutations, 10.3% (79/770); RET fusions, 10.3% (79/770); and NTRK3 fusion, 3.9% (30/770). Notably, the 4-gene NGS panel demonstrated brilliant diagnostic performance for indeterminate cytological nodules (Bethesda categories III-V), achieving a sensitivity of 87.9%, specificity of 96.3%, positive predictive value (PPV) of 99.7%, negative predictive value (NPV) of 35.9%, and overall accuracy of 88.2%. These findings indicate that the targeted NGS 4-gene panel provides high diagnostic precision in distinguishing benign from malignant nodules. Its implementation offers a cost-effective, efficient molecular diagnostic strategy that may reduce unnecessary diagnostic procedures and facilitate optimized clinical management. - Source: PubMed
Jiao QiongWu LingWei BingLi QingSu XulingSun KeyangZhang XiaoyueLuo YanliLiu Zhiyan - Sinonasal adenocarcinomas (SNACs) are the second most common carcinoma category in the sinonasal tract after squamous cell carcinomas and include intestinal type adenocarcinoma, non-intestinal type adenocarcinomas and salivary-type adenocarcinomas. Improved morphologic and molecular characterization have established that most non-ITAC are phenotypically seromucinous with several provisional subtypes (BRAF V600E-mutated sinonasal ductal-like tumors, MAPK/PI3-K altered SNAC, CTNNB1-mutated sinonasal carcinoma, fusion-kinase associated SNAC e.g. ETV6::NTRK3, FGFR-rearranged biphasic SNAC). We report two biphasic/ bicellular ("oncocytic" and "basaloid") SNACs, with multimodal omics characterization, to further underscore the biological complexity of these tumors. One oncocytic case showed HRAS and AKT1 activating mutations; the other basaloid case had a FGFR2::SORB3 fusion. Spatial transcriptomics revealed divergent intra- and inter-tumoral signatures emphasizing the transcriptomic heterogeneity within biphasic components. - Source: PubMed
Publication date: 2026/05/04
Bell DianaWeber Randal SZhang MiaoAfkhami MichelleSeethala Raja R